Project Grant R01EY035887
Award Date
7/1/25
Completion Date
4/30/29
Dollars Obligated
$659K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14642, USA
Similar Awards
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $253,500.00 to the Icahn School of Medicine at Mount Sinai to reconstruct a human blood-retina barrier and perfused vascular system. The goal is to investigate the role of apolipoprotein E (APOE) variants in age-related macular degeneration (AMD), a leading cause of vision loss. The research aims to optimize an in vitro outer blood-retina barrier model, generate isogenic models with different APOE...
This Project Grant award of $620,149 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports a multi-center research program to develop advanced genome editing technologies for modifying critical genetic risk factors associated with age-related macular degeneration (AMD). The research team, led by the University of Iowa, will conduct base editing and prime editing of AMD risk loci in human cells, including induced pluripotent stem...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $240,713 to investigate the role of the nuclear-encoded humanin isoform MTRNR2L1 in the pathogenesis of age-related macular degeneration (AMD), a leading cause of blindness. The research aims to elucidate whether MTRNR2L1 is a protein-coding gene or long non-coding RNA, and to examine its function in regulating mitochondrial activity and cell survival in retinal pigment epithelial cells under stress...
This federal Project Grant award, provided by the National Eye Institute (CFDA 93.867 Vision Research), supports research at the Whitehead Institute for Biomedical Research to systematically identify and characterize novel oxidative protective genes that can prevent retinal pigment epithelium (RPE) degeneration and age-related macular degeneration (AMD). The $173,016 award, effective from Aug 1, 2025 to Jul 31, 2027, will fund a project focused on three primary aims: 1) elucidating the...
This $1,330,026 Project Grant awarded by the National Eye Institute (CFDA 93.867 - Vision Research) will support the development of two new mouse models of geographic atrophy, the advanced form of dry age-related macular degeneration (AMD). The goal is to use these models to evaluate the potential of a novel antioxidant, deuterated docosahexaenoic acid (D-DHA), to protect the retinal pigment epithelium and prevent or treat AMD progression. The research will be conducted by the University of...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) will provide $1,173,062 to The University of Iowa to investigate the role of extracellular matrix stiffness and genetic risk factors in age-related macular degeneration (AMD)-associated epithelial-to-mesenchymal transition. The research aims to determine how changes in matrix biomechanics impact the fate of retinal pigmented epithelial and choroidal endothelial cells using in vitro and ex vivo models of...
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) for $3,120,397 will support the development and characterization of a 3D tissue chip model of the retinal pigment epithelium (RPE)-choroid complex to study the role of genetic risk factors and environmental stressors in the early pathogenesis of age-related macular degeneration (AMD). The research team, led by investigators at the Medical University of South Carolina, will utilize induced pluripotent stem...
The National Eye Institute (NEI) awarded a $291,375 Project Grant (CFDA 93.867 - Vision Research) to the University of Connecticut Health Center to develop a novel mouse model for studying age-related choroidal neovascularization (ARCNV), a key hallmark of wet age-related macular degeneration (AMD). The award, spanning from August 1, 2024 to July 31, 2026, aims to systematically characterize the ARCNV model, which mimics the genetic, environmental, and age-related factors associated with wet...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $638,625 to the University of California, San Diego (UCSD) to develop a "Bruch's Membrane-on-a-Chip" technology for studying the formation of drusen deposits, a key factor in the progression of age-related macular degeneration (AMD). The research aims to investigate the determinants of lipoprotein retention in Bruch's membrane, including the role of apolipoprotein composition and heparan...
This federal Project Grant award under the National Institutes of Health National Eye Institute's Vision Research program (CFDA 93.867) provides $513,371.00 to The Ohio State University to investigate the mechanisms by which oxidative stress triggers cellular signaling pathways that contribute to age-related macular degeneration (AMD) and other debilitating ocular diseases. The 5-year project aims to elucidate how oxidative stress causes the release of self-DNA into the cytosol, activating the...